Atherosclerosis
Volume 148, Issue 1 , Pages 125-129 , January 2000

Genetic polymorphism of heparan sulfate proteoglycan (Perlecan, HSPG2), lipid profiles and coronary artery disease in the Australian population

Received 21 January 1999 ,Revised 5 April 1999 ,Accepted 2 June 1999.

References 

  1. Williams KJ, Fuki IV. Cell-surface heparan sulfate proteoglycans: dynamic molecules mediating ligand catabolism. Curr. Opin. Lipidol. 1997;8:253–262
  2. Yanagishita M, Hascall VC. Cell surface heparan sulfate proteoglycans. J. Biol. Chem. 1992;267:9451–9454
  3. Lindahl U, Kusche-Gullberg M, Kjellén L. Regulated diversity of heparan sulfate. J. Biol. Chem. 1998;273:24979–24982
  4. Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang LJ. Heparan sulfate proteoglycans of the cardiovascular system: specific structures emerge but how is synthesis regulated. J. Clin. Invest. 1997;99:2026–2070
  5. Radhakrishnamurthy B, Tracy RE, Dalferes ER, Berenson GS. Proteoglycans in human coronary arteriosclerotic lesions. Exp. Mol. Pathol. 1998;65:1–8
  6. Tao Z, Smart FW, Figueroa JE, Glancy DL, Vijayagopal P. Elevated expression of proteroglycans in proliferating vascular smooth muscle cells. Atherosclerosis. 1997;135:171–179
  7. Evanko SP, Raines EW, Ross R, Gold LI, Wight TN. Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-deriving growth factor and transforming growth factor-beta. Am. J. Pathol. 1998;152:533–546
  8. Noonan DM, Fulle A, Valente P, Cai S, Horigan E, Sasaki M, et al. The complete sequence of perlecan, a basement membrane heparan sulfate proteglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J. Biol. Chem. 1991;266:22939–22947
  9. Murdoch AD, Dodge GR, Cohen I, Tuan RS, Iozzo RV. Primary structure of the human heparan sulfate proteglycan from basement membrane (HSPG2/Perlecan). J Biol. Chem. 1992;267:8544–8557
  10. Hansen PM, Chowdhury T, Eckert T, Hellgren A, Bain SC, Pociot F. Genetic variation of the heparan sulfate proteglycan gene (perlecan gene). Diabetes. 1997;46:1658–1659
  11. Mangrum A, Bakris GL. Predictors of renal and cardiovascular motality in patients with non-insulin-dependent diabetes: a brief review of microalbuminuria and insulin resistance. J. Diabetes Complications. 1997;11:352–357
  12. Deckert T, Yokoyama H, Mathiesen E, Ronn B, Jensen T, Feldt-Rasmussen B, et al. Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes. Br. Med. J. 1996;312:871–874
  13. Lydakis C, Lip GY. Microalbuminuria and cardiovascular risk. Q. J. Med. 1998;91:381–391
  14. Wang XL, Tam C, McCredie RM, Wilcken DEL. Determinants of severity of coronary artery disease in Australian men and women. Circulation. 1994;89:1974–1981
  15. Emery AEH. Hardy–Weinberg equilibrium the estimation of gene frequencies. In:  Emery AEH editors. Methodology in Medical Genetics: An Introduction to Statistical Methods. Edinburgh: Churchill Livingstone; 1976;p. 3–9
  16. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherosclerosis. J. Lipid Res. 1996;37:693–707
  17. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis. 1998;139:205–222
  18. Mahley RW, Ji Z-S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 1999;40:1–16

PII: S0021-9150(99)00213-0

Atherosclerosis
Volume 148, Issue 1 , Pages 125-129 , January 2000

Article Tools

* Image Usage & Resolution